287 lines
48 KiB
Text
287 lines
48 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK548802">
|
|
<meta name="ncbi_domain" content="livertox">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK548802/?report=reader">
|
|
<meta name="ncbi_pagename" content="Brentuximab Vedotin - LiverTox - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Brentuximab Vedotin - LiverTox - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/livertox/Bremelanotide/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/livertox/Brexanolone/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/livertox/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]">
|
|
<meta name="citation_title" content="Brentuximab Vedotin">
|
|
<meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="citation_date" content="2024/01/10">
|
|
<meta name="citation_pmid" content="31644109">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548802/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Brentuximab Vedotin">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="DC.Date" content="2024/01/10">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548802/">
|
|
<meta name="description" content="Brentuximab vedotin is a chimeric mouse-human monoclonal antibody to CD30 conjugated to a microtubule inhibitor, which is used in the therapy of Hodgkin lymphoma and anaplastic large cell lymphoma. Brentuximab vedotin has been linked to mild and transient serum enzyme elevations during therapy, but has not been implicated in cases of clinically apparent acute liver injury.">
|
|
<meta name="og:title" content="Brentuximab Vedotin">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Brentuximab vedotin is a chimeric mouse-human monoclonal antibody to CD30 conjugated to a microtubule inhibitor, which is used in the therapy of Hodgkin lymphoma and anaplastic large cell lymphoma. Brentuximab vedotin has been linked to mild and transient serum enzyme elevations during therapy, but has not been implicated in cases of clinically apparent acute liver injury.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548802/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/livertox/Brentuximab_vedotin/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548802/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8EEB447D7C3D61000000000013000F.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK548802/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/livertox/Bremelanotide/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Brentuximab Vedotin</div><div class="j">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</div></div><div class="tail"><a href="/books/n/livertox/Brexanolone/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK548802/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK548802/&text=Brentuximab%20Vedotin"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/livertox/?report=reader">Title Information</a><a href="/books/n/livertox/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK548802/?report=classic">Switch to classic view</a><a href="/books/NBK548802/pdf/Bookshelf_NBK548802.pdf">PDF (107K)</a><a href="/books/NBK548802/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK548802%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8EEB447D7C3D61000000000013000F.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK548802_"><span class="title" itemprop="name">Brentuximab Vedotin</span></h1><p class="fm-aai"><a href="#_NBK548802_pubdet_">Publication Details</a></p></div></div><div class="body-content whole_rhythm" itemprop="text"><div id="Brentuximab_vedotin.OVERVIEW"><h2 id="_Brentuximab_vedotin_OVERVIEW_">OVERVIEW</h2><div id="Brentuximab_vedotin.Introduction"><h3>Introduction</h3><p>Brentuximab vedotin is a chimeric mouse-human monoclonal antibody to CD30 conjugated to a microtubule inhibitor, which is used in the therapy of Hodgkin lymphoma and anaplastic large cell lymphoma. Brentuximab vedotin has been linked to mild and transient serum enzyme elevations during therapy, but has not been implicated in cases of clinically apparent acute liver injury.</p></div><div id="Brentuximab_vedotin.Background"><h3>Background</h3><p>Brentuximab (bren tux’ i mab) vedotin (ve doe’ tin) is a chimeric mouse-human monoclonal antibody conjugate used as therapy for adults with Hodgkin lymphoma and anaplastic large cell lymphoma. The monoclonal conjugate is an IgG1 antibody to the human CD30 cell surface marker (also known as tumor necrosis factor receptor superfamily, member 8) which is expressed on malignant cells, particularly in Hodgkin lymphoma. The monoclonal antibody is conjugated to a microtubule inhibitor, monomethyl auristatin E (MMAE, also known as vedotin). When brentuximab vedotin binds to CD30, it is internalized and the MMAE is released by the action of lysosomal enzymes on the linker molecule that joins brentuximab to vedotin. The released vedotin causes apoptotic cell death of the cancerous cell. Brentuximab vedotin has been shown to be effective in inducing remissions in refractory Hodgkin lymphoma and anaplastic large cell lymphoma, and was approved for these indications in the United States in 2011. Brentuximab is available as a 50 mg lyophilized powder in single dose vials for reconstitution under the brand name Adcetris. The recommended regimen is 1.8 mg/kg by intravenous infusion every three weeks until disease progression or unacceptable toxicity. Dose reduction to 1.2 mg/kg is recommended for patients with mild liver dysfunction and avoidance of its use entirely in patients with moderate or severe liver dysfunction. Despite this fact, brentuximab vedotin has been used successfully in patients with Hodgkin disease and vanishing bile duct syndrome with serum bilirubin higher than 20 mg/dL. Common side effects include infusion reactions, peripheral neuropathy, fatigue, nausea, diarrhea, headache, skin rash, chills, fever, leucopenia and thrombocytopenia. Less common, but serious side effects include infections, severe cutaneous reactions including Stevens Johnson syndrome, tumor lysis syndrome, peripheral neuropathy, pulmonary toxicity and progressive multifocal leukoencephalopathy. Brentuximab should be prescribed and administered only by health care workers with expertise and experience in cancer chemotherapy and management of its adverse events.</p></div><div id="Brentuximab_vedotin.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In publications on the large scale trials of brentuximab vedotin, rates of ALT elevations and clinically apparent liver injury were usually not mentioned. In a study of squamous cell carcinoma of the head and neck described in the product label, ALT elevations occurred in 45% of persons receiving brentuximab vedotin and radiation therapy versus 22% of those receiving radiation alone, but elevations above 5 times the ULN were rare (2% vs 1%). Isolated instances of transient serum aminotransferase elevations have been described with brentuximab vedotin therapy in the literature, usually arising during the initial course of treatment. The initial product label for brentuximab vedotin mentioned serious hepatotoxicity occurring in approximately 1% of patients including fatalities and recommended monitoring of liver enzyme and bilirubin levels during therapy. Subsequently, there has been at least one clinical description of severe acute liver injury with jaundice attributed to brentuximab vedotin, reports of 5 possible such cases from the sponsor, and 37 cases reported to the FDA’s Adverse Event Reporting System (FAERS).</p><p>Likelihood score: B (likely cause of clinically apparent liver injury).</p></div><div id="Brentuximab_vedotin.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The cause of the serum enzyme elevations during brentuximab vedotin therapy is not known. However, the antibody conjugate or its break down products may be taken up and metabolized in liver cells to a small extent and cause direct hepatotoxicity. The cases of clinically apparent liver injury attributed to brentuximab vedotin have not resembled sinusoidal obstruction syndrome.</p></div><div id="Brentuximab_vedotin.Outcome_and_Manageme"><h3>Outcome and Management</h3><p>The serum aminotransferase elevations that occur on brentuximab vedotin therapy are generally transient, mild and asymptomatic, and do not require dose modification or delay in therapy. Elevations above 5 times the upper limit of normal should lead to more careful monitoring and discontinuation or delay in therapy until levels return to normal or near normal levels. Serum ALT elevations above 20 times the ULN or with symptoms or jaundice should prompt permanent discontinuation. There is no information on cross reactivity of liver injury among the different monoclonal antibody conjugates.</p><p>Drug Class: <a href="/books/n/livertox/AntineoplasticAgents/?report=reader">Antineoplastic Agents</a>, <a href="/books/n/livertox/MonoclonalAntibodies/?report=reader">Monoclonal Antibodies</a></p><p>Other Monoclonal Antibody Conjugates: Benlantamab Mafodotin, Enfortumab Vedotin, Gemtuzumab Ozogamicin, Inotuzumab Ozogamicin, Polatuzumab Vedotin, Sacituzumab Govitecan, Tisotumab Vedotin, Trastuzumab Deruxtecan, Trastuzumab Emtansine</p></div></div><div id="Brentuximab_vedotin.PRODUCT_INFORMATION"><h2 id="_Brentuximab_vedotin_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Brentuximab vedotin – Adcetris®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Antineoplastic Agents</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?label=all&query=Brentuximab" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Brentuximab_vedotin.CHEMICAL_FORMULA_AND"><h2 id="_Brentuximab_vedotin_CHEMICAL_FORMULA_AND_">CHEMICAL FORMULA AND STRUCTURE</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figBrentuximabvedotinTc"><a href="/books/NBK548802/table/Brentuximab_vedotin.Tc/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figBrentuximabvedotinTc" rid-ob="figobBrentuximabvedotinTc"><img class="small-thumb" src="/books/NBK548802/table/Brentuximab_vedotin.Tc/?report=thumb" src-large="/books/NBK548802/table/Brentuximab_vedotin.Tc/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Brentuximab_vedotin.Tc"><a href="/books/NBK548802/table/Brentuximab_vedotin.Tc/?report=objectonly" target="object" rid-ob="figobBrentuximabvedotinTc">Table</a></h4></div></div></div><div id="Brentuximab_vedotin.ANNOTATED_BIBLIOGRAP"><h2 id="_Brentuximab_vedotin_ANNOTATED_BIBLIOGRAP_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 10 January 2024</p><p>Abbreviations used: ABVD: Adriamycin, bleomycin, vincristine, and dacarbazine; HCT, hematopoietic cell transplantation; TNF, tumor necrosis factor.</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Brentuximab_vedotin.REF.reuben.2011">Reuben A. Hepatotoxicity of immunosuppressive drugs. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2011, pp. 569-91.<div><i>(Review of hepatotoxicity of immunosuppressive agents mentions rituximab and problems of reactivation of hepatitis B, but also states that "the biological immunosuppressants are largely free from hepatotoxicity, with the exception of the TNF alpha antagonists").</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.wellstein.2018">Wellstein A, Giaccone G, Atkins MB, Sausville EA. Pathway-targeted therapies: monoclonal antibodies, protein kinase inhibitors, and various small molecules. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1203-36.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.bradley.2013.589">Bradley
|
|
AM, Devine
|
|
M, DeRemer
|
|
D. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.
|
|
Am J Health Syst Pharm
|
|
2013; 70: 589-97.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/23515511" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23515511</span></a>]<div><i>(Review of the pharmacology, efficacy and safety of brentuximab vedotin; discussion of adverse events does not mention hepatotoxicity or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.rothe.2012.1470">Rothe
|
|
A, Sasse
|
|
S, Goergen
|
|
H, Eichenauer
|
|
DA, Lohri
|
|
A, Jäger
|
|
U, Bangard
|
|
C, et al.
|
|
Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.
|
|
Blood
|
|
2012; 120: 1470-2.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/22786877" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22786877</span></a>]<div><i>(Among 45 patients with refractory Hodgkin lymphoma treated with 1-12 courses of brentuximab vedotin, side effects included peripheral neuropathy [31%], neutropenia [13%], thrombocytopenia [7%], fatigue and infections; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.pro.2012.2190">Pro
|
|
B, Advani
|
|
R, Brice
|
|
P, Bartlett
|
|
NL, Rosenblatt
|
|
JD, Illidge
|
|
T, Matous
|
|
J, et al.
|
|
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
|
|
J Clin Oncol
|
|
2012; 30: 2190-6.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/22614995" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22614995</span></a>]<div><i>(Among 58 patients with systemic anaplastic large cell lymphoma treated with 1 to 16 cycles of brentuximab vedotin, 85% had an objective response and side effects were common, but ALT elevations and hepatotoxicity were not mentioned).</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.gopal.2012.560">Gopal
|
|
AK, Ramchandren
|
|
R, O'Connor
|
|
OA, Berryman
|
|
RB, Advani
|
|
RH, Chen
|
|
R, Smith
|
|
SE, et al.
|
|
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.
|
|
Blood
|
|
2012; 120: 560-8.
|
|
[<a href="/pmc/articles/PMC3731651/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3731651</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22510871" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22510871</span></a>]<div><i>(Among 24 patients with recurrent Hodgkin lymphoma after HCT, 50% had an objective response to brentuximab vedotin and common side effects were cough, fatigue, fever, nausea, neuropathy and dyspnea, and common laboratory abnormalities were leucopenia, thrombocytopenia and decrease in phosphate; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.younes.2012.2183">Younes
|
|
A, Gopal
|
|
AK, Smith
|
|
SE, Ansell
|
|
SM, Rosenblatt
|
|
JD, Savage
|
|
KJ, Ramchandren
|
|
R, et al.
|
|
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
|
|
J Clin Oncol
|
|
2012; 30: 2183-9.
|
|
[<a href="/pmc/articles/PMC3646316/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3646316</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22454421" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22454421</span></a>]<div><i>(Among 102 patients with recurrent Hodgkin lymphoma after HCT who were treated with brentuximab vedotin, peripheral neuropathy occurred in 42%; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.newland.2013.93">Newland
|
|
AM, Li
|
|
JX, Wasco
|
|
LE, Aziz
|
|
MT, Lowe
|
|
DK. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
|
|
Pharmacotherapy
|
|
2013; 33: 93-104.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/23307550" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23307550</span></a>]<div><i>(Review of mechanism of action, pharmacokinetics, efficacy and safety of brentuximab vedotin lists adverse effects of neutropenia [54-55%], peripheral neuropathy [52-53%], fatigue [41-49%], nausea [38-42%], diarrhea [29-36%], anemia [33-52%], fever [29-38%], rash [27-31%] and rare instances of anaphylaxis, tumor lysis syndrome, Stevens-Johnson syndrome, and progressive multifocal leukoencephalopathy [PMLE]; no mention of hepatotoxicity or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.carson.2014.2464">Carson
|
|
KR, Newsome
|
|
SD, Kim
|
|
EJ, Wagner-Johnston
|
|
ND, von Geldern
|
|
G, Moskowitz
|
|
CH, Moskowitz
|
|
AJ, et al.
|
|
Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.
|
|
Cancer
|
|
2014; 120 (16): 2464-71.
|
|
[<a href="/pmc/articles/PMC4460831/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4460831</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24771533" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24771533</span></a>]<div><i>(Clinical description of 5 cases of progressive multifocal leukoencephalopathy arising during brentuximab vedotin therapy; usually after 2-6 doses, 3-34 weeks after starting, presenting with aphasia, dysarthria, confusion, hemiparesis or gait disturbance; 4 of 5 patients died 6-16 weeks after onset).</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.monjanel.2014.306">Monjanel
|
|
H, Deville
|
|
L, Ram-Wolff
|
|
C, Venon
|
|
MD, Franchi
|
|
P, Benet
|
|
C, de Kerviler
|
|
E, et al.
|
|
Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients.
|
|
Br J Haematol
|
|
2014; 166 (2): 306-8.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/24673542" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24673542</span></a>]<div><i>(Among 45 patients with Hodgkin lymphoma or large cell lymphoma treated with brentuximab vedotin, 1 patient had "grade 3 hepatic cytolysis" that was rapidly reversible).</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.urru.2014.9">Urru
|
|
SA, Mariotti
|
|
E, Carta
|
|
P, Massidda
|
|
S, Marcias
|
|
M, Murru
|
|
R, Sanna
|
|
P, Angelucci
|
|
E. Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: a case report.
|
|
Drugs R D
|
|
2014; 14: 9-11.
|
|
[<a href="/pmc/articles/PMC3964296/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3964296</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24493291" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24493291</span></a>]<div><i>(65 year old man with refractory Hodgkin lymphoma developed elevated ALT levels after 1st infusion and nausea and epigastric pain shortly after 2nd leading to hospitalization [amylase 206 U/L, lipase 429 U/L, ALT and bilirubin 2-3 times ULN, neutropenia], but with rapid recovery and subsequent tolerance of further regimens).</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.younes.2014.27">Younes
|
|
A.
|
|
Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma.
|
|
Hematol Oncol Clin North Am
|
|
2014; 28: 27-32.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/24287065" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24287065</span></a>]<div><i>(Short review of the efficacy of brentuximab vedotin in Hodgkin lymphoma; no mention of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.chalasani.2015.1340">Chalasani
|
|
N, Bonkovsky
|
|
HL, Fontana
|
|
R, Lee
|
|
W, Stolz
|
|
A, Talwalkar
|
|
J, Reddy
|
|
KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study.
|
|
Gastroenterology
|
|
2015; 148: 1340-52.e7.
|
|
[<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25754159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 49 [5%] were attributed to antineoplastic agents and 5 [0.5%] to monoclonal antibodies [infliximab, adalimumab and ipilimumab], but none were linked specifically to brentuximab).</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.chen.2015.2136">Chen
|
|
R, Palmer
|
|
JM, Martin
|
|
P, Tsai
|
|
N, Kim
|
|
Y, Chen
|
|
BT, Popplewell
|
|
L, et al.
|
|
Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma.
|
|
Biol Blood Marrow Transplant
|
|
2015; 21: 2136-40.
|
|
[<a href="/pmc/articles/PMC4639410/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4639410</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26211987" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26211987</span></a>]<div><i>(Among 37 patients with refractory Hodgkin lymphoma treated with brentuximab vedotin for a total of 4 cycles, overall response rate was 68%, the "toxicity profile was mild" and ALT elevations occurred in 38%, although none were above 5 times ULN or associated with jaundice).</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.kim.2015.3750">Kim
|
|
YH, Tavallaee
|
|
M, Sundram
|
|
U, Salva
|
|
KA, Wood
|
|
GS, Li
|
|
S, Rozati
|
|
S, et al.
|
|
Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi-institution collaborative project.
|
|
J Clin Oncol
|
|
2015; 33: 3750-8.
|
|
[<a href="/pmc/articles/PMC5089160/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5089160</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26195720" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26195720</span></a>]<div><i>(Among 32 patients with mycosis fungoides or Sézary syndrome treated with brentuximab vedotin every 3 weeks for up to 16 courses, 21 [64%] had a clinical response and common adverse events included peripheral neuropathy [66%], fatigue [47%], nausea [28%] and neutropenia [19%], but there was no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.gupta.2016.e11">Gupta
|
|
A, Petrasek
|
|
J, Sen
|
|
S, Gopal
|
|
P, Naina
|
|
HV. Single-agent brentuximab as bridging therapy for Hodgkin lymphoma patients with hepatic impairment.
|
|
Clin Lymphoma Myeloma Leuk.
|
|
2016;16:e11-4.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/26775723" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26775723</span></a>]<div><i>(Among 5 patients presenting with Hodgkin disease and unexplained liver abnormalities with jaundice [bilirubin 7-21 mg/dL, ALT 67-1187 U/L, Alk P 254-1223 U/L] thought to be due to hepatic lymphoma in 2, vanishing bile duct syndrome in 2, and drug induced liver injury 1, who were treated with brentuximab vedotin as first line therapy, all had at least a partial response and improvement in the liver abnormalities that then allowed standard first line therapy with doxorubicin, bleomycin, vincristine and dacarbazine [ABVD]).</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.prince.2017.555">Prince
|
|
HM, Kim
|
|
YH, Horwitz
|
|
SM, Dummer
|
|
R, Scarisbrick
|
|
J, Quaglino
|
|
P, Zinzani
|
|
PL, et al; ALCANZA study group. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
|
|
Lancet
|
|
2017; 390 (10094): 555-66.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/28600132" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28600132</span></a>]<div><i>(Among 131 patients with refractory T cell lymphomas treated with brentuximab vedotin or standard therapy, objective response rates were 56% vs 13%, and neuropathy occurred in 45% vs 2%; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.fong.2019.e227676">Fong
|
|
M, Boyle
|
|
S, Gutta
|
|
N. Brentuximab vedotin in combination with sequential procarbazine, cyclophosphamide and prednisolone for the management of Hodgkin's lymphoma-associated vanishing bile duct syndrome (VBDS) with severe obstructive liver failure.
|
|
BMJ Case Rep.
|
|
2019;12:e227676.
|
|
[<a href="/pmc/articles/PMC6388893/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6388893</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30796069" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30796069</span></a>]<div><i>(39 year old woman with Hodgkin disease and vanishing bile duct syndrome [bilirubin rising to 26.3 mg/dL] was treated with cycles of cyclophosphamide and prednisone, with addition of procarbazine [cycle 3] and brentuximab vedotin [cycle 4] had an eventual excellent response [by cycle 7] and return of liver tests to normal, allowing for subsequent treatment with first line therapy [ABVD]).</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.neeman.2019.2283">Neeman
|
|
J, Friedman
|
|
A, McKendrick
|
|
J. Acute liver injury leading to death in the setting of brentuximab vedotin monotherapy.
|
|
Leuk Lymphoma.
|
|
2019;60:2283-2286.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/30822188" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30822188</span></a>]<div><i>(67 year old man with composite lymphoma for 11 years was treated with brentuximab vedotin after his third relapse resulting in a partial response but presentation with jaundice and fever after the 7<sup>th</sup> cycle [bilirubin 11.2 mg/dL, ALT 206 U/L, Alk P 745 U/L], a liver biopsy showing cholestatic hepatitis and subsequent progressive course and death from hepatic failure 3-4 weeks later; mentions that the sponsor knew of 5 other possible cases of brentuximab vedotin severe liver injury).</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.ishitsuka.2022.154">Ishitsuka
|
|
K, Yokoyama
|
|
Y, Baba
|
|
N, Matsuoka
|
|
R, Sakamoto
|
|
N, Sakamoto
|
|
T, Kusakabe
|
|
M, et al.
|
|
Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events.
|
|
J Clin Exp Hematop.
|
|
2022;62:154-157.
|
|
[<a href="/pmc/articles/PMC9635035/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9635035</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35831099" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35831099</span></a>]<div><i>(35 year old man with Hodgkin lymphoma and vanishing bile duct syndrome [bilirubin rising to 19.9 mg/dL, Alk P to 2861 U/L] failed to respond to convention anti-lymphoma therapies, but had a partial response and improvement in liver tests with full dose cycles of brentuximab vedotin).</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.wang.2023.2973">Wang
|
|
Y, Wang
|
|
Z, Wei
|
|
C, Zhao
|
|
D, Zhang
|
|
Y, Wang
|
|
W, Zhang
|
|
W, et al.
|
|
Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases.
|
|
Ann Hematol.
|
|
2023;102:2973-2975.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/37522969" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37522969</span></a>]<div><i>(Two cases, 51 year old woman and 31 year old man who presented with Hodgkin disease and severe liver test abnormalities [bilirubin 27.4 mg/dL in one, ALT 1122 U/L in the other], both had improvements in liver tests with first line therapy with brentuximab vedotin and allowed for later use of radiation or ABVD therapy achieving complete remissions).</i></div></div></li><li><div class="bk_ref" id="Brentuximab_vedotin.REF.sun.2023.1">Sun
|
|
C, Yang
|
|
X, Tang
|
|
L, Chen
|
|
J.
|
|
A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system.
|
|
Expert Opin Drug Saf.
|
|
2023:1-12.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/37898875" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37898875</span></a>]<div><i>(Analysis of the FDA reporting system [FAERS] for cases of drug induced liver injury submitted between 2004 and 2022, found 17,784 reports, 504 [3%] attributed to antibody-drug conjugates, 202 from the US, the implicated agents being gemtuzumab ozogamicin [n=98], brentuximab vedotin [n=37], trastuzumab emtansine [n=25], enfortumab vedotin [n=16], inotuzumab ozogamicin [n=15], transtuzumab deruxtecan [n=8], and polatuzumab vedotin [3]).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK548802_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">January 10, 2024</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Brentuximab Vedotin. [Updated 2024 Jan 10].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/livertox/Bremelanotide/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/livertox/Brexanolone/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobBrentuximabvedotinTc"><div id="Brentuximab_vedotin.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548802/table/Brentuximab_vedotin.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Brentuximab_vedotin.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Brentuximab_vedotin.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Brentuximab_vedotin.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NO.</th><th id="hd_h_Brentuximab_vedotin.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Brentuximab_vedotin.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Brentuximab_vedotin.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Brentuximab Vedotin</td><td headers="hd_h_Brentuximab_vedotin.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/135300399" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">914088-09-8</a>
|
|
</td><td headers="hd_h_Brentuximab_vedotin.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Monoclonal Antibody</td><td headers="hd_h_Brentuximab_vedotin.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not Available</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|